DOSE MODIFICATION FOR CHINESE PATIENTS ON NIRAPARIB MAINTENANCE TREATMENT FOR PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A POST HOC ANALYSIS

被引：0
|
作者：
Liu, Z. [1 ]
Wu, X. [2 ]
Zhu, J. [3 ]
Yin, R. [4 ,5 ]
Yang, J. [6 ]
Liu, J. [7 ]
Wang, J. [8 ]
Wu, L. [9 ]
Tan, T. [10 ]
Dong, J. [10 ]
机构：
[1] First Hosp Jilin Univ, Dept Oncol, Changchun, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai, Peoples R China
[3] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Gynecol Oncol, Hangzhou, Peoples R China
[4] Sichuan Univ, West China Univ Hosp 2, Dept Obstet & Gynecol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gynecol Oncol, Beijing, Peoples R China
[7] Sun Yat Sen Univ, Canc Ctr, Dept Gynecol Oncol, Guangzhou, Peoples R China
[8] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Gynecol Oncol, Changsha, Peoples R China
[9] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Gynecol Oncol, Beijing, Peoples R China
[10] Zai Lab Shanghai Co Ltd, RandD Dept, Shanghai, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷
关键词：
D O I：
10.1136/ijgc-2021-ESGO.333
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
29
引用
收藏
页码：A193 / A194
页数：3
相关论文
共 50 条
  • [21] NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A GEICO STUDY WITHIN THE SPANISH EXTENDED ACCESS PROGRAM
    Cueva Banuelos, J. F.
    Palacio, I.
    Churruca, C.
    Herrero-Ibanez, A.
    Pardo, B.
    Constenla, M.
    Santaballa, A.
    Manso, L.
    Estevez, P.
    Maximiano, C.
    Legeren, M.
    Marquina, G.
    De Juan, A.
    Quindos, M.
    Sanchez, L.
    Barquin, A.
    Fernandez Perez, I.
    Martin-Lorente, C.
    Juarez, A.
    Gonzalez-Martin, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A261 - A261
  • [22] Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer
    Nakamura, Keiichiro
    Matsuoka, Hirofumi
    Yorimitsu, Masae
    Ogawa, Mariko
    Kanemori, Miho
    Sueoka, Kotaro
    Kozai, Ayumi
    Nakamura, Hiroko
    Haruma, Tomoko
    Shiroyama, Yuko
    Hayata, Yuu
    Sugii, Hirokazu
    Ueda, Akiko
    Kurihara, Shuichi
    Urayama, Saiko
    Shimizu, Miyuki
    Masuyama, Hisashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (01) : 31 - 37
  • [23] Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study
    Itamochi, Hiroaki
    Takeshima, Nobuhiro
    Hamanishi, Junzo
    Hasegawa, Kosei
    Matsuura, Motoki
    Miura, Kiyonori
    Nagao, Shoji
    Nakai, Hidekatsu
    Tanaka, Naotake
    Tokunaga, Hideki
    Nishio, Shin
    Watari, Hidemichi
    Yokoyama, Yoshihito
    Kase, Yoichi
    Sumino, Shuuji
    Kato, Ai
    Suri, Ajit
    Yasuoka, Toshiaki
    Takehara, Kazuhiro
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [24] Efficacy of Niraparib Maintenance Therapy in Chinese Women With Platinum-Sensitive Recurrent Ovarian Cancer With and Without Secondary Cytoreductive Surgery: Results From the NORA Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 17 - 18
  • [25] Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer
    Hanker, L.
    Valentine, M. C.
    Perhanidis, J. A.
    Hawkes, C.
    Thaker, P. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 241 - 241
  • [26] Cost-effectiveness of maintenance niraparib with an individualized starting dosage compared to routine surveillance in patients with platinum-sensitive recurrent ovarian cancer in China
    Shi, Yin
    Xiao, Di
    Li, Shuishi
    Liu, Shao
    Zhang, Yu
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A74 - A76
  • [27] Management of platinum-sensitive recurrent ovarian cancer
    Pfisterer, Jacobus
    Ledermann, Jonathan A.
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : S12 - S16
  • [28] Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer
    Valentine, Mark
    Perhanidis, Jessica
    Hawkes, Carol
    Thaker, Premal
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S158 - S158
  • [29] Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer
    Moss, Haley A.
    Perhanidis, Jessica A.
    Havrilesky, Laura J.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 50 - 56
  • [30] BUDGET IMPACT ANALYSIS OF NIRAPARIB AND OLAPARUB AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE, RECURRENT OVARIAN CANCER IN THE US
    Wu, L.
    Zhong, L.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
12345